TITLE:
Effect of the Oncology Pack Supplement on Preoperative Nutritional Status and Recovery in Patients with Operable Gastrointestinal Cancer: Prospective Case Series
AUTHORS:
Alberto Suárez Cuevas, Ivanis Ruizcalderon Cabrera, Olga N. Rodríguez Marrero, Marta Lugioyo Lugo, Mircea Betancourt Cabeza, Rosa M. Ortiz Reyes, Ramón de J. Ropero Toirac, David Márquez Soriano
KEYWORDS:
Gastrointestinal Cancer, Immunonutrition, Perioperative Period, Nutritional Status, Postoperative Complications
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.16 No.9,
September
22,
2025
ABSTRACT: Introduction: Malnutrition is a common condition in cancer patients, especially those with tumours located in the digestive tract, and it is associated with increased postoperative morbidity. Nutritional intervention in the perioperative period may improve the surgical prognosis. Oncology Pack (CATALYSIS S.L., Spain) is a product that combines immunonutrients and probiotics, with the potential to optimise nutritional status in this context. Objective: To evaluate the effect of perioperative administration of the Oncology Pack supplement on nutritional status in patients with operable gastrointestinal cancer. Materials and Methods: An observational, prospective study was conducted in 37 patients with gastrointestinal cancer and a surgical indication. The Oncology Pack was administered for 15 days prior to and for 15 days after surgery. Nutritional status was assessed using the Patient-Generated Subjective Global Assessment (PG-SGA) prior to administration and on postoperative day 15. Changes in overall scores and individual components were analysed. Results: 89.2% of patients were at high nutritional risk at baseline. After treatment, a significant reduction in the proportion of patients at high risk was observed (from 89.2% to 40.5%; p = 0.019), with improvement in the weight, food intake, and symptom components of the PG-SGA (p Conclusion: The perioperative use of Oncology Pack was associated with a significant improvement in nutritional status in patients with gastrointestinal cancer. These findings support its potential as an immunonutritional support strategy in enhanced recovery protocols. Controlled clinical trials are required to confirm these results and assess the product’s impact on the incidence of complications associated with oncological surgery.